Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-snake venom monoclonal cocktail
- Development stage
- Preclinical
- Lead developer
- Mediclone Biotech
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Anti-snake venom monoclonal cocktail is an investigational monoclonal antibody cocktail being developed by Mediclone Biotech for the treatment of snakebite envenomation. Funded in part by the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC) of India, the therapy is designed as an alternative to traditional equine-derived polyclonal antivenoms. It consists of a cocktail of monoclonal F(ab')2 fragments intended to neutralize the venom toxins of India's 'Big Four' venomous snakes: the Indian cobra (*Naja naja*), common krait (*Bungarus caeruleus*), Russell's viper (*Daboia russelii*), and saw-scaled viper (*Echis carinatus*). The program is currently in preclinical development.
- Other names
- Anti Snake Venom Serum ASVS using monoclonal F ab2 cocktailAnti Snake Venom Serum ASVS using monoclonal F(ab')2 cocktailAnti-snake venom monoclonal F(ab')2 cocktailAnti-snake venom monoclonal antibody cocktail
02
Targets
RVV-X (Russell's viper venom factor X activator)ECV (Saw-scaled viper venom)
Beyond the preview
Go deeper on anti-snake venom monoclonal cocktail.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-snake venom monoclonal cocktail.